hypo-CASHNCT06695741
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
StatusTerminated
PhasePhase 2
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: No significant improvement in efficacy was observed. Show 6 more changesShow less
- Eligibility criteria expanded, about 15 words
- Final enrollment: 14 participants (planned 75)
- Primary completion date changed from estimate of Feb 1, 2027 to May 1, 2025
- Study completion date changed from estimate of Jun 30, 2027 to Jun 30, 2025
- Secondary endpoints: details revised at 1 of 5 entries
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
Overall response rate
Timeframe: Within 3 months
Secondary (5)
Superior response rate
Overall response rate
Incidence of the adverse event
Time to achieve robust superior response
First time to response
Arms and interventions
hypo-CASHExperimental
ALG/CsA and herombopag and reduced dose of cyclophosphamide
Drugs: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
Sites
1 site in 1 country
- Red Blood Cell Disorders Center and Regenerative Medicine CenterTianjin, Tianjin Municipality, China